Amazing multidisciplinary collaboration with rigorous adjudication at each site. Key points: *HRS is uncommon in the US (12.1%) *ATN is important and we need to start shifting our focus to this important etiology

RT @acv69cardenas: Check out our latest article. Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal h…

RT @ruben_hernaez: TCorticosteroids in severe alcohol-associated hepatitis? Not so fast! @avegailf @HEP_Journal @rabataller @KanwalFasiha…

RT @salvatore_piano: @KavishPatidar11 @md_myer @ebtapper @JoeCullaro ⏰ Early treatment of HRS-AKI is key, but how early is too early? Fact…

@AnandVKulkarni2 @ebtapper Agree. This is way forward. Ideally we need a “troponin” for HRS-AKI for early Terli.

@ebtapper @md_myer Agree. If a patient has AKI and is not responding to initial management suitable to the clinical picture, need to treat early. Keep in mind HRS-AKI occurs relatively infrequently, and you are most likely dealing with pre-renal (hypovoluemia) or ATN (

@md_myer @ebtapper @salvatore_piano @JoeCullaro

@geneyim @DebbieShawcros1 @ebtapper @AmerGastroAssn @MarkThursz @EwanForrest1 I completely agree with @geneyim STOPAH didn’t have Lille stopping criteria either. The recent Anakinra vs prednisone showed a 90% 90 day survival rate in prednisone as the design incorporated Lille stopping criteria.

Kickstarting the inaugural GLOBAL LIVER SAFETY EXPERTS @cancun with THE expert @nagachalasani @avantsantemx @rajVuppaLanchi @orman_md @lilydaramd @craiglammertIU

RT @ruben_hernaez: @KavishPatidar11 breaking ground research presented @AASLDtweets @HealioGastro @bcm_gihep -way to go!

RT @HCPLiveNews: Hear from @KavishPatidar11 of @bcmhouston as he discusses the impact of country-level socioeconomic status and healthcare…

@ebtapper @AnandVKulkarni2 @tony_breu Let’s do it! I will DM you and Anand set up a meeting.

@RoyAHep @AASLDtweets @AnandVKulkarni2 @docMPK @ebtapper @JasmohanBajaj @INASL_Liver @DrMarkMuthiah @DrKaushalMadan1 @Apichatka @ChengHanNg @kumarrahul0204 @SahajRathi @drnipunverma @doc_arka @drsuniltaneja @surmmcian2k6 @AsraniSumeet @BlaneyMD Such a well done study. This is practice changing. Congratulations to @AnandVKulkarni2 and coauthors.

@NnekaUfereMD @mclean_diaz @MGH_GI @MGHKidneys Let’s do it!

@NnekaUfereMD @mclean_diaz @MGH_GI @MGHKidneys Love this paper! I think it’s the first to describe the decision making processes in LT ineligible patients. Hopefully we can build of your work!

@BlaneyMD @NIAAAnews @AASLDtweets Completely agree. In a large “real world” cohort, we showed moderate AH carried a 12% rate and 1/3 were readmitted within 90 days. MAUD can prevent re-admissions. ➡️

@yuvalpatelMD @JoeCullaro @ebtapper The rationale would be that large volume shifts could increase AKI risk. CKD and number of L removed increase AKI risk (). Also, recently published in the AJG (, even 3-5L can ⬆️ sCr.

@ruben_hernaez @AASLDtweets I had an awesome mentor @AsraniSumeet to make it happen.

@ruben_hernaez @bcm_gihep @AmJGastro @IUGastro @AzizullahBeran Completely agree. Never too late!